Real-world evidence of the management and prognosis of young women (⩽40 years) with metastatic breast cancer

Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. De novo metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. Methods: We evaluated management of women ag...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in medical oncology 2022-01, Vol.14
Main Authors: Amélie Mallet, Amélie Lusque, Christelle Levy, Barbara Pistilli, Etienne Brain, David Pasquier, Marc Debled, Jean Christophe Thery, Anthony Gonçalves, Isabelle Desmoulins, Thibault De La Motte Rouge, Christelle Faure, Jean Marc Ferrero, Jean Christophe Eymard, Marie Ange Mouret-Reynier, Anne Patsouris, Paul Cottu, Florence Dalenc, Thierry Petit, Olivier Payen, Lionel Uwer, Séverine Guiu, Jean Sébastien Frenel
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. De novo metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. Methods: We evaluated management of women aged ⩽40 years with de novo MBC in a real-life national multicentre cohort of 22,463 patients treated between 2008 and 2016 (NCT0327531). Our primary objective was to compare overall survival (OS) in young women versus women aged 41–69 years. The secondary objectives were to compare first-line progression-free survival (PFS1) and to describe treatment patterns. Results: Of the 4524 women included, 598 (13%) were ⩽40 years. Median age at MBC diagnosis was 36 years (range = 20–40). Compared with women aged 41–69 years, young women had more grade III tumours (49% versus 35.7%, p  
ISSN:1758-8359
DOI:10.1177/17588359211070362